- Home
- GBDC vs SLNO Comparison
GBDC vs SLNO Comparison
Compare GBDC & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBDC
- SLNO
- Stock Information
- Founded
- GBDC 2009
- SLNO 1999
- Country
- GBDC United States
- SLNO United States
- Employees
- GBDC N/A
- SLNO N/A
- Industry
- GBDC Finance: Consumer Services
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GBDC Finance
- SLNO Health Care
- Exchange
- GBDC Nasdaq
- SLNO Nasdaq
- Market Cap
- GBDC 3.7B
- SLNO 3.8B
- IPO Year
- GBDC 2010
- SLNO 2014
- Fundamental
- Price
- GBDC $13.48
- SLNO $63.91
- Analyst Decision
- GBDC Buy
- SLNO Strong Buy
- Analyst Count
- GBDC 3
- SLNO 9
- Target Price
- GBDC $15.00
- SLNO $116.78
- AVG Volume (30 Days)
- GBDC 1.9M
- SLNO 2.4M
- Earning Date
- GBDC 11-18-2025
- SLNO 11-05-2025
- Dividend Yield
- GBDC 11.77%
- SLNO N/A
- EPS Growth
- GBDC N/A
- SLNO N/A
- EPS
- GBDC 1.41
- SLNO N/A
- Revenue
- GBDC $877,342,000.00
- SLNO $32,656,999.00
- Revenue This Year
- GBDC $23.63
- SLNO N/A
- Revenue Next Year
- GBDC N/A
- SLNO $182.29
- P/E Ratio
- GBDC $9.62
- SLNO N/A
- Revenue Growth
- GBDC 31.97
- SLNO N/A
- 52 Week Low
- GBDC $12.68
- SLNO $41.50
- 52 Week High
- GBDC $16.01
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- GBDC 32.34
- SLNO 50.30
- Support Level
- GBDC $13.51
- SLNO $59.68
- Resistance Level
- GBDC $13.91
- SLNO $64.38
- Average True Range (ATR)
- GBDC 0.23
- SLNO 4.08
- MACD
- GBDC -0.01
- SLNO 0.89
- Stochastic Oscillator
- GBDC 5.06
- SLNO 68.52
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.